Category: QB3
In business, the decision to support an initiative is frequently made following a live presentation supported by slides. Too often these presentations miss the mark. Cruxio specializes in equipping biomedical companies to develop and deliver clear, powerful strategic stories - usually as live presentations. In the past four years, Cruxio's unique story-development methodology has fueled more than 50 mission-critical presentations, helping to secure more than $500 million in funds or revenue. Join Rob Wishnowsky, founder of Cruxio - the crux of the story - for an interactive overview of five essentials you need to consider to develop your clear, compelling strategic story.
In 2005 Rob Wishnowsky founded Cruxio (the crux of the story), a West Coast company that helps companies develop and deliver clear strategic stories. Cruxio's proprietary processes have been used in more than fifty presentations, securing more than $500 million in funding or revenue. Rob has extensive experience in global strategy, sales and marketing in the fields of life science, diagnostics and biotechnology. 20 years he has led business units, sales forces, strategy formulation, market segmentation, portfolio development and marketing execution, primarily in large corporations (Boehringer Mannheim/Roche Diagnostics, Johnson & Johnson's Lifescan) as well as in early-stage companies. He served on the board of the Biomedical Marketing Association from 2003 to 2007.
Lunch provided, but space is limited so please reserve a seat at http://www.acteva.com/booking.cfm?bevaID=206505
 |
|
Mission Bay Capital
|
|
qed@qb3 UCSF
Thursday, June 3, 2010
12:00 to 1:00 pm
Byers Hall Room 212
|
In this presentation, the QB3/ Mission Bay Capital (MBC) team will describe our services for entrepreneurs. We are dedicated to helping QB3 faculty, students, and staff bring the benefits of scientific innovation to society. One way to do this is by creating successful new companies. Our Innovation Toolkit-a suite of services that includes mentoring, incubator space, and pre-commercial funding-helps entrepreneurs move ideas from the lab to the market. To give new companies that final boost to viability, we have now added a vital component to the Innovation Toolkit: MBC, a seed stage $8.5 million venture capital fund.
Regis Kelly, QB3 Director, is a distinguished neuroscientist and former executive vice chancellor of UCSF (from October, 2001 until January 31, 2004). As executive vice chancellor, Kelly oversaw the UCSF research enterprise, which now totals about $465 million annually. He also forged new research ties between the university and private industry. Kelly directs the institute at its headquarters on UCSF's Mission Bay campus and also maintains a Berkeley office.
Douglas Crawford, QB3 Associate Executive Director, created and manages the QB3 Garage@UCSF and the QB3 Mission Bay Incubator Network, which have helped launch 27 companies. He is a founder and the managing director of Mission Bay Capital. Crawford acts as a Knowledge Broker between the QB3 campuses and the bio-pharmaceutical industry. He is also a board member of BayBio Institute, and BioE2E. Crawford received his Ph.D. in biochemistry at UCSF.
Tracy Saxton, QB3 Alliance Management Director, manages the UC-Pfizer alliance. Prior to joining QB3 in 2008, Saxton held positions at Bay Area biotechnology companies Tularik/Amgen, Threshold Pharmaceuticals, and Geron Corporation. She began her diverse career as a drug discovery scientist, and moved to leadership roles in global regulatory affairs, clinical development, business development and project management. She obtained her Ph.D. in molecular genetics from the University of Toronto.
| Lunch provided, but space is limited so please reserve a seat at http://www.acteva.com/booking.cfm?bevaID=203912 |
 |
|
Intellectual Property Protection:
The Basics
|
|
qed@qb3 - Berkeley
Friday, June 6, 2010
12:00 to 1:00 pm
Stanley Hall Atrium
|
Protecting inventions and trade secrets is a basic requirement for technology start-ups. The process generally involves interfacing with the office of technology transfer of the University and patent attorneys. The legal jargon and patenting process can be daunting and is filled with pitfalls. Understanding the basics of IP protection is a fundamental requirement for all scientists and corporate officers. Once there is an invention, what steps must a start-up follow in order to secure patent protection. Dr. Joseph R. Snyder is a patent attorney and partner in the chemistry and biotechnology group of Townsend and Townsend and Crew. His presentation will focus on understanding the basic requirements for patenting a chemical or a biotechnical invention.
Dr. Joseph R. Snyder's practice emphasizes patent drafting, patent procurement, client counseling, and opinion writing, primarily in the chemical arts, biotechnology, life sciences and clean technology. He counsels clients on planning and portfolio analysis for patent protection, including strategic review of technologies' commercial potential; in the enforcement of patent rights; and in the defense of infringement allegations. He conducts and performs due diligences investigations in connection with commercial transactions, such as mergers, acquisitions, and the establishment of strategic business alliances. These investigations involve intellectual property including patents, technology licenses, acquisition agreements, and asset purchase agreements. He also advises on the creation of start-ups and their patent portfolio development, coordinating the transfer and licensing of intellectual property as it relates to office of technology transfer agreements, collaborative/ sponsored research agreements, and other transfer agreements. He worked as a patent attorney for Zeneca Ag Products. Prior to becoming a patent attorney, he was a senior scientist in their analytical department. Joseph received a PhD in Chemistry from Notre Dame and a JD from USF.
Lunch provided, but space is limited so please reserve a seat at http://www.acteva.com/booking.cfm?bevaID=204217
| |
|
Killing Pain with Killer Snails: The Development of the Analgesic, Prialt®
|
|
qed@qb3 - Berkeley
Friday, May 7, 2010
12:00 to 1:00 pm
Stanley Hall Room 621
|
Ziconotide is the first intraspinal analgesic approved in the U.S. (2004) for the management of severe chronic pain in more than two decades. Ziconotide, the synthetic equivalent of a 25 amino acid neuroactive peptide originally isolated from the magician's cone snail, is a potent, selective blocker of neuronal N-type voltage-gated calcium channels that mediate the propagation and processing of noxious stimuli by pain pathway neurons. Ziconotide has its own unique safety issues, but as a non-opiate analgesic, it does not suffer from many of the limitations of opiate analgesics. The safety and efficacy of ziconotide have been well documented in several clinical trials and, subsequently, through the experience of thousands of additional pain patients. The history of the development and commercialization, as well as speculations on future uses of Ziconotide, will be discussed.
Dr. George Miljanich has been developing ion channel therapeutics, analgesics, and peptide-based drugs for more than 20 years. As CEO at Airmid, he leads the development of T-cell potassium channel blockers to treat autoimmune disorders. Prior to Airmid, he was Senior Director at Elan Pharmaceuticals, playing a key role in the clinical development, regulatory approval, and commercialization of the analgesic, PRIALT® (ziconotide), Dr. Miljanich received a BS and PhD in Chemistry from UC Berkeley and UC Santa Cruz, respectively, and conducted post-doctoral research at UC San Francisco with Prof. Regis Kelly. On the faculty at the USC, he studied calcium channels and calcium channel-blocking conotoxins. Dr. Miljanich then moved to Neurex Corp. to translate these conotoxins into pharmaceuticals, contributing to the development of PRIALT from invention through Phase III trials. With the acquisition of Neurex, he became head of analgesia research at Elan. Dr. Miljanich recently co-founded SiteOne Therapeutics with researchers at Stanford to develop analogues of the sodium channel blocker, saxitoxin, as treatments for a variety of pain syndromes. He has authored numerous scientific publications and is co-inventor on 17 U.S. patents. He serves as a consultant to the pharmaceutical industry and is Vice President of the Toxinomics Foundation and a member of the CONCO initiative. The Foundation fosters development of toxin-based therapeutics and CONCO is a $12-million 20-lab EU-based program devoted to discovering and developing drugs from animal toxins.
Lunch provided, but space is limited so please reserve a seat at http://www.acteva.com/booking.cfm?bevaID=201425
|
|
Angel Investing
|
|
qed@qb3 UCSF
Tuesday, May 4, 2010
12:00 to 1:00 pm
Byers Hall Room 212
|
This session will provide a real-world introduction to the theory and practice of entrepreneurship, exploring the various strategic, financial and organizational challenges faced during a long but successful entrepreneurial journey that has led Frank Peters to angel investing.
Frank Peters founded Plaid Brothers Software which developed portfolio management systems for Wall Street firms. After bootstrapping the company for 15 years he sold it in 1998 to Sungard Data Systems. Frank has been an active investor in early-stage companies since 1999. He was a founding member of Charlotte Angel Partners in Charlotte, North Carolina, then he moved to Orange County and joined the Tech Coast Angels, eventually becoming Chairman. Frank is a prolific podcaster featured in his Frank Peters Show where he interviews entrepreneurs and angel investors. Frank is a member of the Dean's Leadership Council in the Claire Trevor School of the Arts at UC Irvine.
Lunch provided, but space is limited so please reserve a seat at http://www.acteva.com/booking.cfm?bevaID=202129
http://qb3.org/services/qed-qb3/?searchterm=qed
| |
|
Mission Bay Capital
|
|
qed@qb3 - Berkeley
Friday, April 2, 2010
12:00 to 1:00 pm
Stanley Hall Room 621
|
In this presentation, the QB3/ Mission Bay Capital(MBC) team will describe our services for entrepreneurs. We are dedicated to helping QB3 faculty, students, and staff bring the benefits of scientific innovation to society. One way to do this is by creating successful new companies. Our Innovation Toolkit-a suite of services that includes mentoring, incubator space, and pre-commercial funding-helps entrepreneurs move ideas from the lab to the market. To give new companies that final boost to viability, we have now added a vital component to the Innovation Toolkit: MBC, a seed stage $8.5 million venture capital fund.
Regis Kelly, QB3 Director, is a distinguished neuroscientist and former executive vice chancellor of UCSF (from October, 2001 until January 31, 2004). As executive vice chancellor, Kelly oversaw the UCSF research enterprise, which now totals about $465 million annually. He also forged new research ties between the university and private industry. Kelly directs the institute at its headquarters on UCSF's Mission Bay campus and also maintains a Berkeley office.
Douglas Crawford, QB3 Associate Executive Director, created and manages the QB3 Garage@UCSF and the QB3 Mission Bay Incubator Network, which have helped launch 27 companies. He is a founder and the managing director of Mission Bay Capital. Crawford acts as a Knowledge Broker between the QB3 campuses and the bio-pharmaceutical industry. He is also a board member of BayBio Institute, and BioE2E. Crawford received his Ph.D. in biochemistry at UCSF.
Tracy Saxton, QB3 Alliance Management Director, manages the UC-Pfizer alliance. Prior to joining QB3 in 2008, Saxton held positions at Bay Area biotechnology companies Tularik/Amgen, Threshold Pharmaceuticals, and Geron Corporation. She began her diverse career as a drug discovery scientist, and moved to leadership roles in global regulatory affairs, clinical development, business development and project management. She obtained her Ph.D. in molecular genetics from the University of Toronto.
Lunch provided, but space is limited so please reserve a seat at http://www.acteva.com/booking.cfm?bevaID=201474
|
|
Report from the trenches: starting, funding, and growing a life sciences
business in today's economy
|
|
qed@qb3 UCSF
Thursday, April 1, 2010
12:00 to 1:00 pm
Byers Hall Room 212
|
Starting a business in any environment is a difficult proposition.
However, since the economic collapse of 2008 it's gotten even tougher. This session will explore some of the themes that are common to starting any life sciences company, and will look specifically at the current climate and what you can do to put yourself in the best position for success.
Jeff Jensen is the CEO of Fluxion Biosciences, a functional cell analysis tools company and the very first tenant of the QB3 Garage. Jeff joined Fluxion in fall 2006, and has led the company through initial angel financing, a VC round, and subsequent commercialization of two product lines that are now marketed globally to academic and pharma/biotech labs. During his career Jeff has been involved in starting, guiding, and growing a number of life sciences companies, including Eksigent Technologies (drug discovery tools and medical devices), Nodality (molecular diagnostics), and Silicon Kinetics (life science tools). Jeff has a B.S. in chemical engineering from Cornell, and is a graduate of the Program for Management Development at Harvard Business School.
Lunch provided, but space is limited so please reserve a seat at http://www.acteva.com/booking.cfm?bevaID=201422
http://qb3.org/services/qed-qb3/?searchterm=qed
Lean Startup Circle presents:
Sean Ellis Teaches the Keys to Explosive Startup Growth
Sean Ellis has helped companies like Dropbox, EventBrite and Xobni grow 
explosively. His expertise was also essential in guiding Uproar and LogMeIn to IPO. Come to the March 24th Lean Startup Circle at 6:30 pm to find out first hand how he did it. Stay afterwards for drinks sponsored by KISSMetrics and get face time with Sean and other top startup founders.
Get top notch advice from Sean, network with other founders, and enjoy a free dinner and drinks!
Date: Wednesday, March 24th
Time: 6:30 p.m.
Location: Genentech Hall, Byer’s Auditorium
UCSF faculty and students are free to attend. ID is required.
Sponsored by KISSMetrics and QB3 Garage.
| |
|
Slicing the Pie: Entity Formation and the Division of Equity
|
|
qed@qb3 - UCB
Friday, March 5, 2010
12:00 to 1:00 pm
Stanley Hall Room 621
|
Matt Kirmayer will lead a discussion of the issues relating to forming an entity, seeding it with the assets and IP to be successful, and avoiding the potential pitfalls when dividing up the equity among the founders.
Matt Kirmayer is a member in the Corporate practice. His practice is focused on the representation of emerging technology companies, venture capital and private equity funds and institutional investors. Matt represents clients in many industries, such as multimedia, wireless technologies, networking, internet infrastructure and security, nanotechnology, life sciences and medical devices. He also represents NY Money Center Banks and institutional investors in capital market transactions. Prior to joining Mintz Levin, Matt was a partner at a San Francisco area law firm. Matt began his career in New York City handling securities offerings and merger and acquisition transactions. Matt is admitted to practice law in California and New York. He received a J.D. from Rutgers University and an LL.M. from New York University School of Law.
Lunch provided, but space is limited so please reserve a seat here.
http://qb3.org/services/qed-qb3/?searchterm=qed
|
|
...But what do I know?
Lessons learned from living through a couple of spin-out companies
|
|
qed@qb3 UCSF
Thursday, March 4, 2010
12:00 to 1:00 pm
Byers Hall Room 212
|
There are many lessons to be learned in the formation of spinouts. Tom will walk through his experiences going from an academic setting to a spinout company and what he has learned from this and a couple of other companies that he has been close to (Avantome, TrueMaterials, Boreal Genomics)
Tom Willis is the CEO of MLC Dx Inc. a VC backed company dedicated to the commercialization of molecular diagnostic tests. Prior to founding MLC, Tom has been an entrepreneur in the biotech industry for the past decade. After receiving his Ph.D. in physics from Stanford University, he joined the Stanford Genome Technology Center (SGTC) to work on DNA sequence analysis technologies. He held several positions at the SGTC including Associate Director in charge of technology development. While at SGTC, he co-invented the Molecular Inversion Probe technology for high throughput genotyping. In 2001, he co-founded ParAllele BioScience to develop and commercialize this technology. As its founding CEO, he led ParAllele through two rounds of VC financing a grew the company to over 80 employees. In 2005 ParAllele was acquired by Affymetrix at which time Tom served in several management positions at Affymetrix. He left in 2007 to pursue new startup opportunities. In addition to his role at MLC, Tom serves on the boards of SpinX Technologies and Boreal Genomics
Lunch provided, but space is limited so please reserve a seat at http://www.acteva.com/booking.cfm?bevaID=198455
http://qb3.org/services/qed-qb3/?searchterm=qed
